First Horizon Advisors Inc. Decreases Stake in Edwards Lifesciences Corporation $EW

First Horizon Advisors Inc. reduced its position in Edwards Lifesciences Corporation (NYSE:EW) by 14.2% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 8,488 shares of the medical research company’s stock after selling 1,403 shares during the period. First Horizon Advisors Inc.’s holdings in Edwards Lifesciences were worth $664,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in EW. Quantbot Technologies LP bought a new stake in shares of Edwards Lifesciences in the first quarter valued at approximately $26,000. SouthState Corp purchased a new position in Edwards Lifesciences in the 1st quarter valued at approximately $27,000. Rosenberg Matthew Hamilton bought a new stake in Edwards Lifesciences during the 2nd quarter valued at $28,000. Costello Asset Management INC purchased a new stake in shares of Edwards Lifesciences during the first quarter worth $29,000. Finally, NewSquare Capital LLC lifted its position in shares of Edwards Lifesciences by 57.8% during the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after acquiring an additional 134 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Activity

In related news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on EW shares. Piper Sandler reiterated an “overweight” rating and set a $95.00 price objective (up from $90.00) on shares of Edwards Lifesciences in a research note on Friday, October 31st. Citigroup upped their price target on Edwards Lifesciences from $95.00 to $96.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Wednesday, October 8th. Mizuho boosted their price objective on shares of Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. Finally, Daiwa America upgraded shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 29th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $91.39.

Edwards Lifesciences Price Performance

EW opened at $82.42 on Friday. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $48.39 billion, a P/E ratio of 11.86, a PEG ratio of 3.97 and a beta of 1.03. The stock has a 50-day moving average price of $77.74 and a 200-day moving average price of $77.21. Edwards Lifesciences Corporation has a 12-month low of $64.89 and a 12-month high of $87.09.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The company had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences’s quarterly revenue was up 14.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.